Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
Investigational drug GM604 has shown some intriguing results in a very small number of ALS patients
Posted on Thursday, January 22, 2015 - 10:13, By: Margaret Wahl
Biopharmaceutical company Genervon has announced what it considers encouraging results from a "compassionate use" trial of its experimental drug GM604 in a single patient with advanced amyotrophic lateral sclerosis (ALS).
Posted on Tuesday, January 13, 2015 - 12:04, By: Margaret Wahl
Update (March 17, 2015): Neuralstem announced on March 12, 2015, that a phase 2 trial to test transplantation into the spinal cord of its NSI-566 neural stem cells showed the procedure was generally safe and well tolerated in 15 ALS patients (with one exception) and that stabilization or...
Stanford University is collecting samples of blood, muscle and other tissues from people with neuromuscular disorders for use in research
Posted on Wednesday, January 7, 2015 - 15:36, By: Margaret Wahl
Ever wondered how someone with a neuromuscular disorder in his or her family might contribute to research efforts in this field?
MDA has joined forces with the ALS Association to fight ALS through a grant to James Shorter at the University of Pennsylvania
Posted on Wednesday, December 3, 2014 - 14:09, By: Margaret Wahl
MDA has joined forces with the ALS Association (ALSA) to fund a new research project aimed at finding a potential therapy for amyotrophic lateral sclerosis (ALS).
The two organizations have made a $240,000 award to molecular biologist James Shorter at the Perelman School of Medicine at the...
Israeli biotechnology company BrainStorm will test its adult stem cells, derived from bone marrow, in 48 ALS patients at three sites
Posted on Friday, June 13, 2014 - 10:06, By: Margaret Wahl
Israeli biotechnology company BrainStorm Cell Therapeutics has enrolled the first participant in a phase 2, U.S.-based trial of adult stem cell transplantation to treat amyotrophic lateral sclerosis (ALS).
Results of a large-scale trial of tirasemtiv in ALS show the drug may slow respiratory decline without improving scores on the ALS Functional Rating Scale
Posted on Thursday, May 1, 2014 - 14:07, By: Margaret Wahl
The experimental drug tirasemtiv, in development by South San Francisco biopharmaceutical company Cyokinetics as a potential treatment for amyotrophic lateral sclerosis (ALS), slowed the decline in at least one measure of respiratory function in a recent, large-scale study known as BENEFIT-ALS (...
An MDA-supported research team has found that expansions of the C9ORF72 gene cause formation of abnormally shaped DNA and RNA, with adverse effects on cells
Posted on Wednesday, April 23, 2014 - 15:11, By: Margaret Wahl
Jiou Wang, an MDA research grantee at Johns Hopkins University, says the new findings could have implications for several disorders.